| Host: |
Rabbit |
| Applications: |
WB/ELISA |
| Reactivity: |
Human/Rat/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Cleaved-Kininogen-1-K380 (300-380 aa) is suitable for use in Western Blot and ELISA research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-1:2000ELISA 1:10000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
KNG1 |
| Gene ID: |
3827 |
| Uniprot ID: |
KNG1_HUMAN |
| Immunogen Region: |
300-380 aa |
| Specificity: |
Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody detects endogenous levels of fragment of activated Kininogen-1 HC protein resulting from cleavage adjacent to K380. |
| Immunogen: |
Synthesized peptide derived from Cleaved-Kininogen-1 HC (K380) at the amino acid range 300-380 |
| Post Translational Modifications | Bradykinin: Bradykinin is inactivated by ACE, which removes the dipeptide Arg-Phe from its C-terminus. Bradykinin is released from kininogen by plasma kallikrein. Hydroxylation of Pro-383 occurs prior to the release of bradykinin. Phosphorylated by FAM20C in the extracellular medium. N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans. (Microbial infection) Bradykinin is generated upon proteolytic cleavage by S.pyogenes SpeB to produce hypotension during septic shock. |
| Function | Kininogens are inhibitors of thiol proteases. HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII.HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. LMW-kininogen inhibits the aggregation of thrombocytes. LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. Bradykinin: The active peptide bradykinin is a potent vasodilatator that is released from HMW-kininogen shows a variety of physiological effects: (A) influence in smooth muscle contraction, (B) induction of hypotension, (C) natriuresis and diuresis, (D) decrease in blood glucose level, (E) it is a mediator of inflammation and causes (E1) increase in vascular permeability, (E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action). |
| Protein Name | Kininogen-1Alpha-2-Thiol Proteinase InhibitorFitzgerald FactorHigh Molecular Weight KininogenHmwkWilliams-Fitzgerald-Flaujeac Factor Cleaved Into - Kininogen-1 Heavy Chain - T-KininIle-Ser-Bradykinin - BradykininKallidin I - Lysyl-BradykininKallidin Ii - Kininogen-1 Light Chain - Low Molecular Weight Growth-Promoting Factor |
| Database Links | Reactome: R-HSA-114608Reactome: R-HSA-140837Reactome: R-HSA-375276Reactome: R-HSA-381426Reactome: R-HSA-416476Reactome: R-HSA-418594Reactome: R-HSA-8957275 |
| Cellular Localisation | SecretedExtracellular Space |
| Alternative Antibody Names | Anti-Kininogen-1 antibodyAnti-Alpha-2-Thiol Proteinase Inhibitor antibodyAnti-Fitzgerald Factor antibodyAnti-High Molecular Weight Kininogen antibodyAnti-Hmwk antibodyAnti-Williams-Fitzgerald-Flaujeac Factor Cleaved Into - Kininogen-1 Heavy Chain - T-Kinin antibodyAnti-Ile-Ser-Bradykinin - Bradykinin antibodyAnti-Kallidin I - Lysyl-Bradykinin antibodyAnti-Kallidin Ii - Kininogen-1 Light Chain - Low Molecular Weight Growth-Promoting Factor antibodyAnti-KNG1 antibodyAnti-BDK antibodyAnti-KNG antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
